IDEAYA Biosciences, Inc. Share Price & Technical Analysis
IDYA · $29.10 (-1.49%)
Healthcare / Biotechnology
$29.10
-1.49%
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and i…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
0% return in May, 5% avg return in past 3 year May month.
-15% return in 2026, 33% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -7% | 0% | 5% | -13% | 0% | – | – | – | – | – | – | – | -15% |
| 25 | -7% | -14% | -22% | 23% | -1% | 6% | 19% | 2% | 5% | 17% | 12% | -2% | 37% |
| 24 | 24% | 2% | -2% | -7% | -11% | -6% | 23% | -8% | -20% | -11% | -3% | -6% | -25% |
| 23 | -7% | 3% | -22% | 34% | 25% | 3% | -5% | 32% | -8% | 1% | 16% | 13% | 86% |
| 22 | -31% | -22% | -16% | -14% | 16% | 22% | 8% | -34% | 51% | 13% | 5% | 2% | -1% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.46B
P/E ratio
—
52W high
$39.28
52W low
$18.77
Volume
4,50,525
Beta
-0.04
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is IDEAYA Biosciences, Inc. share price today?
- IDEAYA Biosciences, Inc. (IDYA) last traded around $29.10 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IDYA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IDYA. Download the app for real-time alerts.
- How can I analyze IDEAYA Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.